BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li Q, Cao M, Yuan G, Cheng X, Zang M, Chen M, Hu X, Huang J, Li R, Guo Y, Ruan J, Chen J. Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study. Front Oncol 2022;12:809709. [PMID: 35280760 DOI: 10.3389/fonc.2022.809709] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Chen Z, Chen Z, Fan W, Zou Y, Zhang Y, Shi N, Jin H. Conversion surgery for advanced hepatocellular carcinoma after combination treatment of lenvatinib and camrelizumab: a case report. World J Surg Oncol 2023;21:29. [PMID: 36721173 DOI: 10.1186/s12957-023-02910-4] [Reference Citation Analysis]
2 Luo J, Gao B, Lin Z, Fan H, Ma W, Yu D, Yang Q, Tian J, Yang X, Li B. Efficacy and safety of lenvatinib versus sorafenib in first-line treatment of advanced hepatocellular carcinoma: A meta-analysis. Front Oncol 2022;12:1010726. [PMID: 36620586 DOI: 10.3389/fonc.2022.1010726] [Reference Citation Analysis]
3 Lei J, Chen B, Song M, Zhang L, Zhang X, Gao X, Li Y, Lu Y, Zuo S. TKI or TKI combined with PD-1 inhibitors as second-line treatment for HCC patients after sorafenib failure. Front Pharmacol 2022;13:1026337. [PMID: 36569315 DOI: 10.3389/fphar.2022.1026337] [Reference Citation Analysis]
4 Chen B, Lei J, Zhao H, Dong J, Zeng Z, Li Y, Yu L, Zhou L, Jia A, Lu Y, Cheng J. Efficacy and Safety of TKI Plus PD-1 Inhibitors in Elderly uHCC Patients: A Retrospective Study. JHC 2022;Volume 9:1171-1185. [DOI: 10.2147/jhc.s387254] [Reference Citation Analysis]
5 Bei H, Mai W, Chen W, Li M, Yang Y. Application of systemic treatment in conversion therapy options for liver cancer. Front Oncol 2022;12:966821. [DOI: 10.3389/fonc.2022.966821] [Reference Citation Analysis]